Ballentine Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.04M | Buy |
24,093
+280
| +1% | +$36.9K | 0.04% | 159 |
|
|
2026
Q1 | $3.32M | Buy |
23,813
+571
| +2% | +$80K | 0.05% | 137 |
|
|
2025
Q4 | $2.85M | Buy |
23,242
+570
| +3% | +$69.3K | 0.04% | 150 |
|
|
2025
Q3 | $2.52M | Buy |
22,672
+1,041
| +5% | +$118K | 0.03% | 163 |
|
|
2025
Q2 | $2.4M | Sell |
21,631
-1,740
| -7% | -$185K | 0.04% | 169 |
|
|
2025
Q1 | $2.62M | Buy |
23,371
+1,535
| +7% | +$158K | 0.05% | 149 |
|
|
2024
Q4 | $2.02M | Buy |
21,836
+1,956
| +10% | +$176K | 0.03% | 172 |
|
|
2024
Q3 | $1.67M | Buy |
19,880
+8,451
| +74% | +$645K | 0.03% | 199 |
|
|
2024
Q2 | $784K | Buy |
11,429
+378
| +3% | +$25.2K | 0.01% | 311 |
|
|
2024
Q1 | $809K | Sell |
11,051
-4,084
| -27% | -$314K | 0.02% | 293 |
|
|
2023
Q4 | $1.23M | Buy |
15,135
+5,702
| +60% | +$444K | 0.03% | 204 |
|
|
2023
Q3 | $707K | Buy |
9,433
+794
| +9% | +$61.1K | 0.02% | 252 |
|
|
2023
Q2 | $666K | Buy |
8,639
+1,466
| +20% | +$117K | 0.02% | 251 |
|
|
2023
Q1 | $595K | Buy |
7,173
+501
| +8% | +$41.5K | 0.02% | 269 |
|
|
2022
Q4 | $573K | Buy |
6,672
+890
| +15% | +$70.5K | 0.02% | 255 |
|
|
2022
Q3 | $357K | Buy |
+5,782
| New | +$365K | 0.01% | 303 |
|
|
2022
Q1 | – | Sell |
-3,404
| Closed | -$248K | – | 490 |
|
|
2021
Q4 | $248K | Buy |
+3,404
| New | +$234K | 0.01% | 400 |
|
|
2021
Q2 | – | Sell |
-3,313
| Closed | -$215K | – | 429 |
|
|
2021
Q1 | $215K | Buy |
+3,313
| New | +$214K | 0.01% | 366 |
|
|
2020
Q4 | – | Sell |
-5,931
| Closed | -$375K | – | 396 |
|
|
2020
Q3 | $375K | Sell |
5,931
-549
| -8% | -$38.1K | 0.02% | 246 |
|
|
2020
Q2 | $498K | Sell |
6,480
-75
| -1% | -$5.75K | 0.02% | 207 |
|
|
2020
Q1 | $490K | Buy |
6,555
+873
| +15% | +$60.3K | 0.03% | 190 |
|
|
2019
Q4 | $369K | Buy |
5,682
+203
| +4% | +$13.2K | 0.02% | 265 |
|
|
2019
Q3 | $347K | Buy |
5,479
+106
| +2% | +$6.93K | 0.02% | 261 |
|
|
2019
Q2 | $363K | Buy |
5,373
+400
| +8% | +$26.3K | 0.02% | 261 |
|
|
2019
Q1 | $323K | Buy |
4,973
+234
| +5% | +$15.6K | 0.02% | 236 |
|
|
2018
Q4 | $297K | Sell |
4,739
-841
| -15% | -$58.8K | 0.02% | 248 |
|
|
2018
Q3 | $430K | Sell |
5,580
-60
| -1% | -$4.53K | 0.02% | 218 |
|
|
2018
Q2 | $400K | Sell |
5,640
-208
| -4% | -$14.7K | 0.02% | 214 |
|
|
2018
Q1 | $442K | Sell |
5,848
-761
| -12% | -$60.5K | 0.02% | 195 |
|
|
2017
Q4 | $474K | Sell |
6,609
-1,484
| -18% | -$113K | 0.03% | 200 |
|
|
2017
Q3 | $656K | Sell |
8,093
-456
| -5% | -$34.9K | 0.04% | 164 |
|
|
2017
Q2 | $630K | Buy |
8,549
+3,318
| +63% | +$221K | 0.05% | 165 |
|
|
2017
Q1 | $355K | Sell |
5,231
-327
| -6% | -$23K | 0.03% | 160 |
|
|
2016
Q4 | $399K | Sell |
5,558
-410
| -7% | -$30.5K | 0.03% | 130 |
|
|
2016
Q3 | $472K | Sell |
5,968
-379
| -6% | -$30.8K | 0.04% | 103 |
|
|
2016
Q2 | $530K | Sell |
6,347
-293
| -4% | -$26K | 0.04% | 99 |
|
|
2016
Q1 | $609K | Sell |
6,640
-660
| -9% | -$59.5K | 0.05% | 95 |
|
|
2015
Q4 | $739K | Buy |
7,300
+472
| +7% | +$49.1K | 0.07% | 72 |
|
|
2015
Q3 | $671K | Buy |
6,828
+633
| +10% | +$70.3K | 0.07% | 73 |
|
|
2015
Q2 | $725K | Sell |
6,195
-11
| -0.2% | -$1.2K | 0.07% | 69 |
|
|
2015
Q1 | $609K | Sell |
6,206
-195
| -3% | -$19.8K | 0.06% | 79 |
|
|
2014
Q4 | $604K | Buy |
6,401
+174
| +3% | +$18K | 0.07% | 76 |
|
|
2014
Q3 | $663K | Buy |
6,227
+479
| +8% | +$46.9K | 0.08% | 65 |
|
|
2014
Q2 | $477K | Sell |
5,748
-155
| -3% | -$12.1K | 0.06% | 82 |
|
|
2014
Q1 | $418K | Buy |
5,903
+128
| +2% | +$10K | 0.05% | 84 |
|
|
2013
Q4 | $434K | Sell |
5,775
-442
| -7% | -$30.8K | 0.05% | 87 |
|
|
2013
Q3 | $391K | Buy |
6,217
+2,057
| +49% | +$123K | 0.05% | 90 |
|
|
2013
Q2 | $213K | Buy |
+4,160
| New | +$217K | 0.03% | 115 |
|
Other funds holding GILD
Ballentine Partners's GILD Position: Q2 2026 in Review
Ballentine Partners increased its Gilead Sciences (GILD) stake by 1.2% in Q2 2026, buying an estimated $36.9K and bringing the position to 24,093 shares worth $3.04M. The position accounts for 0.04% of the portfolio, ranked #159.
Ballentine Partners first reported a position in GILD in Q2 2013 and has held it in 48 quarters since. The position peaked at $3.32M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Ballentine Partners held 24,093 shares of Gilead Sciences worth $3.04M as of Q2 2026.
- Ballentine Partners bought 280 Gilead Sciences shares in Q2 2026, an estimated $36.9K.
- Gilead Sciences made up 0.04% of Ballentine Partners's portfolio in Q2 2026, its #159 holding.
- Ballentine Partners first reported a position in Gilead Sciences in Q2 2013 and has held it in 48 quarters since.
- Ballentine Partners's Gilead Sciences position peaked at $3.32M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.